4 Desferrioxamine-induced iron excretion in humans

Bailliere's Clinical Haematology

Volumn 2, Issue 2, 1989, Pages 323-343

  Pippard, Martin J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRIOXAMINE;

DRUG ADMINISTRATION; DRUG DOSE; DRUG MONITORING; DRUG THERAPY; DRUG URINE LEVEL; ERYTHROPOIESIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; PHARMACOKINETICS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DEFEROXAMINE; HUMAN; IRON;

EID: 0024521376     PISSN: 09503536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3536(89)80020-4     Document Type: Article

References (95)

1. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis
2. Mechanism of action of desferoxaminum on iron absorption
3. Measurement of iron stores using deferoxamine
4. Studies on desferrioxamine in relation to the absorption of iron
5. Effect of Desferrioxamine and D.T.P.A. in Iron Overload
6. Long-term chelation in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress
7. Continuous intravenous deferoxamine infusion
8. Long term results of venesection therapy in idiopathic haemochromatosis
9. Rapid desensitisation for desferrioxamine anaphylactoid reactions
10. Studies of the site of action of desferoxamine
11. Iron chelation with oral desferrioxamine
12. Iron chelation therapy with deferoxamine in Cooley anemia
13. Iron chelation therapy in sickle cell anemia
14. Response to long-term deferoxamine therapy in thalassemia
15. Depletion of excessive liver iron stores with desferrioxamine
16. Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia
17. Effects of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine
18. Clinical and laboratory studies on the action of desferrioxamine
19. Ocular toxicity of high-dose intravenous desferrioxamine
20. High dose chelation therapy in thalassaemia
21. Early iron overload in β-thalassaemia major: when to start chelation therapy?
22. Differential ferrioxamine test for measuring chelatable body iron
23. Continuous RBC transfusions in a patient with sickle cell disease
24. Toxicity of desferrioxamine treatment
25. Clinical studies of storage iron with desferrioxamine
26. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron-chelating drug
27. Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine
28. Chelation therapy in β-thalassemia major. III. The role of splenectomy in achieving iron balance
29. Body iron excretion in man
30. Clinical trial of desferrioxamine entrapped in red cell ghosts
31. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts
32. The effect of desferrioxamine on iron metabolism in man
33. The effect of desferrioxamine on iron metabolism in man. II
34. Desferrioxamine-induced urinary iron excretion in normal and iron-deficient subjects
35. Liver Iron and Desferrioxamine-Induced Urinary Iron Excretion
36. Evaluation of storage iron by chelates
37. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats
38. Oral iron chelating drugs: coming but not yet ready for clinical use
39. Mechanism of desferrioxamine-induced iron excretion in thalassaemia
40. Storage iron kinetics. II. The uptake of hemoglobin iron by hepatic parenchymal cells
41. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity
42. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
43. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload
44. Effect of dose, time and ascorbate on iron excretion after subcutaneous desferrioxamine
45. The liver in thalassaemia major: ultrastructural observation.
46. The chelation of iron during intestinal absorption
47. Desferrioxamine chelatable iron in haemolytic, megaloblastic and sideroblastic anaemias
48. The biochemistry of desferrioxamine and its relation to iron metabolism
49. Desferrioxamine suppositories
50. Improvement of iron removal from the reticulo-endothelial system by liposome encapsulation of N,N′-bis (2-hydroxybenzyl)-ethylenediamine-N,N′-diacetic acid (HBED). Comparison with desferrioxamine
51. The role of ascorbic acid in the metabolism of storage iron
52. Desferrioxamine to improve cardiac function in iron-loaded patients with thalassaemia major
53. Rapid desensitisation for desferrioxamine anaphylactic reaction
54. Advances in the use of iron-chelating agents for the treatment of iron overload
55. Long-term desferrioxamine therapy in thalassemia
56. Treatment of Primary and Secondary Hemochromatosis and Acute Iron Poisoning with a New, Potent Iron-Eliminating Agent (Desferrioxamine-B)
57. Influence of desferrioxamine on the renal excretion of iron
58. Vitamin C and iron
59. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload
60. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major
61. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
62. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat
63. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions
64. Iron chelation in thalassemia
65. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies
66. Effect of desferroxamine on transferrin iron metabolism in iron-loaded man
67. Simple assay for urinary iron after desferrioxamine therapy
68. Iron absorption in non-transfused iron-loading anaemias: prediction of risk for iron loading, and response to iron chelation therapy in β thalassaemia intermedia and sideroblastic anaemias
69. Iron balance and the management of iron overload in β-thalassemia intermedia
70. Iron absorption in iron-loading anaemias: effect of subcutaneous desferrioxamine infusions
71. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias
72. Prevention of iron loading in transfusion-dependent thalassaemia
73. Ferrioxamine excretion in iron-loaded man
74. Hepatocyte iron kinetics in the rat explored with an iron chelator
75. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA)
76. Ferritin iron metabolism in the rat liver
77. Desferrioxamine and acute iron poisoning
78. Sideruria following a single dose of desferrioxamine B as a diagnostic test in iron overload
79. Chelate mediated transfer of iron from transferrin to desferrioxamine
80. Reassessment of the use of desferrioxamine B in iron overload
81. Continuous subcutaneous administration of desferoxamine in patients with iron overload
82. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence
83. Chelating agents in the diagnosis and treatment of iron overload in thalassemia
84. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
85. Desferal therapy in iron storage disease
86. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis
87. Desferrioxamine effect on iron excretion in hemochromatosis
88. Effects of iron overload on ascorbic acid metabolism
89. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion
90. Clinical usefulness of iron chelating agents
91. Studies in acute iron poisoning. 1. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations
92. The treatment of haemochromatosis with desferrioxamine
93. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
94. Application of atomic absorption spectrophotometry in the determination of iron in urine